HIV-1 Vpr degrades the HLTF DNA translocase in T cells and macrophages

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 19, 2016, Pages 5311-5316

  Lahouassa, Hichem ^a,b,c,f   Blondot, Marie Lise ^a,b,c,g   Chauveau, Lise ^b,d   Chougui, Ghina ^a,b,c   Morel, Marina ^a,b,c   Leduc, Marjorie ^a,b,c   Guillonneau, François ^a,b,c   Ramirez, Bertha Cecilia ^a,b,c   Schwartz, Olivier ^b,d,e   Margottin Goguet, Florence ^a,b,c  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d INSTITUT PASTEUR   (France)

^e Vaccine Research Institute   (France)

^f HIGHER NATIONAL VETERINARY SCHOOL   (Algeria)

^g UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Dna repair; HIV; Restriction factor; SILAC; Vpr target

Indexed keywords

ADAPTOR PROTEIN; DDB1 CULLIN4 ASSOCIATED FACTOR 1 PROTEIN; DNA BINDING PROTEIN; HELICASE LIKE TRANSCRIPTION FACTOR; PROTEIN TRANSLOCASE; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE CUL4A; UNCLASSIFIED DRUG; VPR PROTEIN; HLTF PROTEIN, HUMAN; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DOWN REGULATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; JURKAT CELL LINE; MACROPHAGE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRUS CELL INTERACTION; CELL CULTURE; METABOLISM; PHYSIOLOGY;

CELLS, CULTURED; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; HELA CELLS; HUMANS; MACROPHAGES; T-LYMPHOCYTES; TRANSCRIPTION FACTORS; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84966372855     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1600485113     Document Type: Article

References (89)

1. Chatzinikolaou G, Karakasilioti I, Garinis GA (2014) DNA damage and innate immunity: Links and trade-offs. Trends Immunol 35(9):429-435.
2. Zeman MK, Cimprich KA (2014) Causes and consequences of replication stress. Nat Cell Biol 16(1):2-9.
3. Crow YJ, Manel N (2015) Aicardi-Goutières syndrome and the type I interferonopathies. Nat Rev Immunol 15(7):429-440.
4. Brégnard C, Benkirane M, Laguette N (2014) DNA damage repair machinery and HIV escape from innate immune sensing. Front Microbiol 5:176.
5. Dedera D, Hu W, Vander Heyden N, Ratner L (1989) Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells. J Virol 63(7):3205-3208.
6. Balliet JW, et al. (1994) Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: Mutational analysis of a primary HIV-1 isolate. Virology 200(2):623-631.
7. Eckstein DA, et al. (2001) HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp Med 194(10):1407-1419.
8. Connor RI, Chen BK, Choe S, Landau NR (1995) Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206(2):935-944.
9. Jacquot G, et al. (2007) Localization of HIV-1 Vpr to the nuclear envelope: Impact on Vpr functions and virus replication in macrophages. Retrovirology 4:84.
10. Zander K, et al. (2003) Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression. J Biol Chem 278(44):43202-43213.
11. de Silva S, Planelles V, Wu L (2012) Differential effects of Vpr on single-cycle and spreading HIV-1 infections in CD4+ T-cells and dendritic cells. PLoS One 7(5):e35385.
12. Mashiba M, Collins DR, Terry VH, Collins KL (2014) Vpr overcomes macrophage-specific restriction of HIV-1 Env expression and virion production. Cell Host Microbe 16(6): 722-735.
13. Collins DR, Lubow J, Lukic Z, Mashiba M, Collins KL (2015) Vpr promotes macrophagedependent HIV-1 infection of CD4+ T lymphocytes. PLoS Pathog 11(7):e1005054.
14. Lang SM, et al. (1993) Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol 67(2):902-912.
15. Beaumont T, et al. (2001) Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J Virol 75(5):2246-2252.
16. Goh WC, et al. (1998) HIV-1 Vpr increases viral expression by manipulation of the cell cycle: A mechanism for selection of Vpr in vivo. Nat Med 4(1):65-71.
17. Caly L, Saksena NK, Piller SC, Jans DA (2008) Impaired nuclear import and viral incorporation of Vpr derived from a HIV long-term non-progressor. Retrovirology 5:67.
18. Hadi K, et al. (2014) Human immunodeficiency virus type 1 Vpr polymorphisms associated with progressor and nonprogressor individuals alter Vpr-associated functions. J Gen Virol 95(Pt 3):700-711.
19. Jacquot G, et al. (2009) Characterization of the molecular determinants of primary HIV-1 Vpr proteins: Impact of the Q65R and R77Q substitutions on Vpr functions. PLoS One 4(10):e7514.
20. Tzitzivacos DB, Tiemessen CT, Stevens WS, Papathanasopoulos MA (2009) Viral genetic determinants of nonprogressive HIV type 1 subtype C infection in antiretroviral drug-naive children. AIDS Res Hum Retroviruses 25(11):1141-1148.
21. Blondot ML, Dragin L, Lahouassa H, Margottin-Goguet F (2014) How SLX4 cuts through the mystery of HIV-1 Vpr-mediated cell cycle arrest. Retrovirology 11(1):117.
22. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V (2003) Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem 278(28):25879-25886.
23. Belzile JP, et al. (2007) HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog 3(7):e85.
24. DeHart JL, et al. (2007) HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. Virol J 4:57.
25. Hrecka K, et al. (2007) Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci USA 104(28):11778-11783.
26. Le Rouzic E, et al. (2007) HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 6(2):182-188.
27. Schröfelbauer B, Hakata Y, Landau NR (2007) HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc Natl Acad Sci USA 104(10):4130-4135.
28. Tan L, Ehrlich E, Yu XF (2007) DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol 81(19):10822-10830.
29. Wen X, Duus KM, Friedrich TD, de Noronha CM (2007) The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J Biol Chem 282(37):27046-27057.
30. Laguette N, et al. (2014) Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell 156(1-2):134-145.
31. Fekairi S, et al. (2009) Human SLX4 is a Holliday junction resolvase subunit that binds multiple DNA repair/recombination endonucleases. Cell 138(1):78-89.
32. Muñoz IM, et al. (2009) Coordination of structure-specific nucleases by human SLX4/ BTBD12 is required for DNA repair. Mol Cell 35(1):116-127.
33. Svendsen JM, et al. (2009) Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell 138(1):63-77.
34. Bouhamdan M, et al. (1996) Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J Virol 70(2):697-704.
35. Selig L, et al. (1997) Uracil DNA glycosylase specifically interacts with Vpr of both human immunodeficiency virus type 1 and simian immunodeficiency virus of sooty mangabeys, but binding does not correlate with cell cycle arrest. J Virol 71(6): 4842-4846.
36. Schröfelbauer B, Yu Q, Zeitlin SG, Landau NR (2005) Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol 79(17):10978-10987.
37. Saugar I, Ortiz-Bazán MA, Tercero JA (2014) Tolerating DNA damage during eukaryotic chromosome replication. Exp Cell Res 329(1):170-177.
38. Ghosal G, Chen J (2013) DNA damage tolerance: A double-edged sword guarding the genome. Transl Cancer Res 2(3):107-129.
39. Sheridan PL, Schorpp M, Voz ML, Jones KA (1995) Cloning of an SNF2/SWI2-related protein that binds specifically to the SPH motifs of the SV40 enhancer and to the HIV-1 promoter. JBiolChem270(9):4575-4587.
40. Hayward-Lester A, et al. (1996) Cloning, characterization, and steroid-dependent posttranscriptional processing of RUSH-1 alpha and beta, two uteroglobin promoterbinding proteins. Mol Endocrinol 10(11):1335-1349.
41. Gong X, et al. (1997) Developmental regulation of Zbu1, a DNA-binding member of the SWI2/SNF2 family. Dev Biol 183(2):166-182.
42. Ding H, et al. (1996) Characterization of a helicase-like transcription factor involved in the expression of the human plasminogen activator inhibitor-1 gene. DNA Cell Biol 15(6):429-442.
43. Zhang Q, Ekhterae D, Kim KH (1997) Molecular cloning and characterization of P113, a mouse SNF2/SWI2-related transcription factor. Gene 202(1-2):31-37.
44. Debauve G, Capouillez A, Belayew A, Saussez S (2008) The helicase-like transcription factor and its implication in cancer progression. Cell Mol Life Sci 65(4):591-604.
45. Sandhu S, et al. (2012) Loss of HLTF function promotes intestinal carcinogenesis. Mol Cancer 11:18.
46. Kim JJ, et al. (2006) Promoter methylation of helicase-like transcription factor is associated with the early stages of gastric cancer with family history. Ann Oncol 17(4): 657-662.
47. Moinova HR, et al. (2002) HLTF gene silencing in human colon cancer. Proc Natl Acad Sci USA 99(7):4562-4567.
48. Lin JR, Zeman MK, Chen JY, Yee MC, Cimprich KA (2011) SHPRH and HLTF act in a damage-specific manner to coordinate different forms of postreplication repair and prevent mutagenesis. Mol Cell 42(2):237-249.
49. Blastyák A, Hajdú I, Unk I, Haracska L (2010) Role of double-stranded DNA translocase activity of human HLTF in replication of damaged DNA. Mol Cell Biol 30(3):684-693.
50. Torres-Ramos CA, Prakash S, Prakash L (2002) Requirement of RAD5 and MMS2 for postreplication repair of UV-damaged DNA in Saccharomyces cerevisiae. Mol Cell Biol 22(7):2419-2426.
51. Blastyák A, et al. (2007) Yeast Rad5 protein required for postreplication repair has a DNA helicase activity specific for replication fork regression. Mol Cell 28(1):167-175.
52. Ong SE, et al. (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1(5): 376-386.
53. Cohen EA, Dehni G, Sodroski JG, Haseltine WA (1990) Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol 64(6):3097-3099.
54. Paxton W, Connor RI, Landau NR (1993) Incorporation of Vpr into human immunodeficiency virus type 1 virions: Requirement for the p6 region of gag and mutational analysis. J Virol 67(12):7229-7237.
55. Maudet C, et al. (2011) Molecular insight into how HIV-1 Vpr protein impairs cell growth through two genetically distinct pathways. J Biol Chem 286(27):23742-23752.
56. Matheson NJ, et al. (2015) Cell surface proteomic map of HIV infection reveals antagonism of amino acid metabolism by Vpu and Nef. Cell Host Microbe 18(4):409-423.
57. Hrecka K, et al. (2011) Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474(7353):658-661.
58. Laguette N, et al. (2011) SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1restriction factor counteracted by Vpx. Nature 474(7353):654-657.
59. Unk I, et al. (2008) Human HLTF functions as a ubiquitin ligase for proliferating cell nuclear antigen polyubiquitination. Proc Natl Acad Sci USA 105(10):3768-3773.
60. Helmer RA, et al. (2013) Helicase-like transcription factor (Hltf) regulates G2/M transition, Wt1/Gata4/Hif-1a cardiac transcription networks, and collagen biogenesis. PLoS One 8(11):e80461.
61. DePaula-Silva AB, et al. (2015) Determinants for degradation of SAMHD1, Mus81 and induction of G2 arrest in HIV-1 Vpr and SIVagm Vpr. Virology 477:10-17.
62. Casey Klockow L, et al. (2013) The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection. Virology 444(1-2): 191-202.
63. Romani B, Shaykh Baygloo N, Hamidi-Fard M, Aghasadeghi MR, Allahbakhshi E (2015) HIV-1 Vpr protein induces proteasomal degradation of chromatin-associated class I HDACs to overcome latent infection of macrophages. J Biol Chem 290:17380-17389.
64. Wang X, et al. (2013) HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1- VPRBP E3 ligase complex. J Biol Chem 288(22):15474-15480.
65. Sharp PM, Bailes E, Stevenson M, Emerman M, Hahn BH (1996) Gene acquisition in HIV and SIV. Nature 383(6601):586-587.
66. Tristem M, Marshall C, Karpas A, Hill F (1992) Evolution of the primate lentiviruses: Evidence from vpx and vpr. EMBO J 11(9):3405-3412.
67. Checroune F, Yao XJ, Gottlinger HG, Bergeron D, Cohen EA (1995) Incorporation of Vpr into human immunodeficiency virus type 1: Role of conserved regions within the P6 domain of Pr55gag. J AIDS Human Retrovirol 10(1):1-7.
68. Selig L, et al. (1999) Interaction with the p6 domain of the gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. J Virol 73(1):592-600.
69. Ayinde D, Maudet C, Transy C, Margottin-Goguet F (2010) Limelight on two HIV/SIV accessory proteins in macrophage infection: Is Vpx overshadowing Vpr? Retrovirology 7:35.
70. Bétous R, et al. (2012) SMARCAL1 catalyzes fork regression and Holliday junction migration to maintain genome stability during DNA replication. Genes Dev 26(2): 151-162.
71. Couch FB, et al. (2013) ATR phosphorylates SMARCAL1 to prevent replication fork collapse. Genes Dev 27(14):1610-1623.
72. Achar YJ, Balogh D, Haracska L (2011) Coordinated protein and DNA remodeling by human HLTF on stalled replication fork. Proc Natl Acad Sci USA 108(34):14073-14078.
73. Burkovics P, Sebesta M, Balogh D, Haracska L, Krejci L (2014) Strand invasion by HLTF as a mechanism for template switch in fork rescue. Nucleic Acids Res 42(3):1711-1720.
74. Hishiki A, et al. (2015) Structure of a novel DNA-binding domain of helicase-like transcription factor (HLTF) and its functional implication in DNA damage tolerance. J Biol Chem 290(21):13215-13223.
75. Allouch A, et al. (2013) p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proc Natl Acad Sci USA 110(42):E3997-E4006.
76. Bergamaschi A, et al. (2009) The CDK inhibitor p21Cip1/WAF1 is induced by FcgammaR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages. J Virol 83(23):12253-12265.
77. Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale M, Jr (2009) Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol 83(20):10395-10405.
78. Majumder B, Venkatachari NJ, Srinivasan A, Ayyavoo V (2009) HIV-1 mediated immune pathogenesis: Spotlight on the role of viral protein R (Vpr). Curr HIV Res 7(2): 169-177.
79. Okumura A, et al. (2008) HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 373(1):85-97.
80. Roesch F, et al. (2015) Vpr enhances tumor necrosis factor production by HIV-1-infected Tcells.JVirol89(23):12118-12130.
81. Sato K, et al. (2013) HIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivo. PLoS Pathog 9(12):e1003812.
82. Kile AC, et al. (2015) HLTF's ancient HIRAN domain binds 3? DNA ends to drive replication fork reversal. Mol Cell 58(6):1090-1100.
83. Wu Y (2012) Unwinding and rewinding: Double faces of helicase? J Nucleic Acids 2012:140601.
84. Baradaran-Heravi A, et al. (2012) SMARCAL1 deficiency predisposes to non-Hodgkin lymphoma and hypersensitivity to genotoxic agents in vivo. Am J Med Genet A 158A(9):2204-2213.
85. Goldstone DC, et al. (2011) HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480(7377):379-382.
86. Lahouassa H, et al. (2012) SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 13(3):223-228.
87. Powell RD, Holland PJ, Hollis T, Perrino FW (2011) Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J Biol Chem 286(51):43596-43600.
88. Duggal NK, Emerman M (2012) Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol 12(10):687-695.
89. Ward J, et al. (2009) HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog 5(10):e1000613.